6826 Stock Overview

Shanghai Haohai Biological Technology Co., Ltd. More details

6826 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	5/6
Financial Health	5/6
Dividends	2/6

Rewards

Trading at 79% below our estimate of its fair value

Earnings are forecast to grow 16.82% per year

Earnings grew by 24.5% over the past year

Risk Analysis

No risks detected for 6826 from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Shanghai Haohai Biological Technology Co., Ltd. Competitors

3SBio

SEHK:1530

HK$14.2b

Shanghai Henlius Biotech

SEHK:2696

HK$13.0b

Shandong Boan Biotechnology

SEHK:6955

HK$4.8b

Essex Bio-Technology

SEHK:1061

HK$1.6b

Price History & Performance

Summary of share price highs, lows and changes for Shanghai Haohai Biological Technology
Historical stock prices
Current Share Price	HK$27.00
52 Week High	HK$42.95
52 Week Low	HK$21.71
Beta	0.77
1 Month Change	1.69%
3 Month Change	-15.76%
1 Year Change	-3.45%
3 Year Change	-18.27%
5 Year Change	n/a
Change since IPO	-40.75%

Recent updates

Shareholder Returns

	6826	HK Biotechs	HK Market
7D	-1.1%	-2.7%	1.5%
1Y	-3.4%	-9.2%	20.6%

Return vs Industry: 6826 exceeded the Hong Kong Biotechs industry which returned -6% over the past year.

Return vs Market: 6826 underperformed the Hong Kong Market which returned 22.4% over the past year.

Price Volatility

Is 6826's price volatile compared to industry and market?
6826 volatility
6826 Average Weekly Movement	7.8%
Biotechs Industry Average Movement	11.5%
Market Average Movement	8.8%
10% most volatile stocks in HK Market	18.6%
10% least volatile stocks in HK Market	4.0%

Stable Share Price: 6826 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 6826's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2007	2,179	Jianying Wu	www.3healthcare.com

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop.

Shanghai Haohai Biological Technology Co., Ltd. Fundamentals Summary

How do Shanghai Haohai Biological Technology's earnings and revenue compare to its market cap?
6826 fundamental statistics
Market cap	HK$13.75b
Earnings (TTM)	HK$457.84m
Revenue (TTM)	HK$2.92b

13.6x

P/E Ratio

2.1x

P/S Ratio

Is 6826 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6826 income statement (TTM)
Revenue	CN¥2.75b
Cost of Revenue	CN¥848.86m
Gross Profit	CN¥1.90b
Other Expenses	CN¥1.47b
Earnings	CN¥430.21m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.87
Gross Margin	69.10%
Net Profit Margin	15.66%
Debt/Equity Ratio	7.0%

How did 6826 perform over the long term?

See historical performance and comparison

Dividends

3.2%

Current Dividend Yield

85%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/25 15:43
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Haohai Biological Technology Co., Ltd. is covered by 17 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jingwei Qi	China Merchants Securities Co. Ltd.
Xiaofang Xu	Citic Securities Co., Ltd.
Eva Zhao	Citigroup Inc